Orchard Therapeutics plc – NASDAQ:ORTX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Orchard Therapeutics stock price monthly change
+1.70%
month
Orchard Therapeutics stock price quarterly change
+4.51%
quarter
Orchard Therapeutics stock price yearly change
+2555.01%
year
Orchard Therapeutics key metrics
Market Cap | 380.10M |
Enterprise value | N/A |
P/E | -0.43 |
EV/Sales | -0.42 |
EV/EBITDA | 0.06 |
Price/Sales | 0.02 |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 7.09 |
Revenue | 21.83M |
EBITDA | 73.00M |
Income | 69.85M |
Revenue Q/Q | 9.08% |
Revenue Y/Y | 35.20% |
Profit margin | -665.02% |
Oper. margin | -561.44% |
Gross margin | 70.11% |
EBIT margin | -561.44% |
EBITDA margin | 334.28% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOrchard Therapeutics stock price history
Orchard Therapeutics stock forecast
Orchard Therapeutics financial statements
| Dec 2022 | 6.98M | 134.89M | 1930.92% |
|---|---|---|---|
| Mar 2023 | 1.23M | -17.41M | -1407.6% |
| Jun 2023 | 7.31M | -12.30M | -168.27% |
| Sep 2023 | 6.30M | -35.31M | -560.44% |
| 2025 | 97.86M | -82.18M | -83.98% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 218907000 | 120.64M | 55.11% |
|---|---|---|---|
| Mar 2023 | 217017000 | 115.36M | 53.16% |
| Jun 2023 | 232302000 | 123.25M | 53.06% |
| Sep 2023 | 202266000 | 122.00M | 60.32% |
| Dec 2022 | -12.08M | -1.56M | -811K |
|---|---|---|---|
| Mar 2023 | -29.50M | -9.34M | 31.50M |
| Jun 2023 | -27.83M | -26.69M | 30.93M |
| Sep 2023 | -23.89M | 11.58M | -2.35M |
Orchard Therapeutics alternative data
| Aug 2023 | 166 |
|---|---|
| Sep 2023 | 166 |
| Oct 2023 | 166 |
| Nov 2023 | 166 |
| Dec 2023 | 166 |
| Jan 2024 | 166 |
| Feb 2024 | 166 |
| Mar 2024 | 166 |
| Apr 2024 | 166 |
| May 2024 | 166 |
| Jun 2024 | 166 |
| Jul 2024 | 166 |
Orchard Therapeutics other data
29.97%
-4.66%
of ORTX is owned by hedge funds
22
-23
3.83M
-601.21K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2022 | 25000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | THOMAS FRANK E officer: See Rema.. | Ordinary Shares | 20,000 | $0.46 | $9,180 | ||
Option | THOMAS FRANK E officer: See Rema.. | Stock Option (Right to Buy) | 20,000 | $0.46 | $9,180 | ||
Option | THOMAS FRANK E officer: Title: P.. | Stock Option (Right to Buy) | 20,000 | $0.46 | $9,180 | ||
Option | THOMAS FRANK E officer: Title: P.. | Ordinary Shares | 20,000 | $0.46 | $9,180 | ||
Purchase | GASPAR BOBBY director, officer.. | Ordinary Shares | 15,000 | $0.74 | $11,085 | ||
Purchase | THOMAS FRANK E officer: Title: P.. | Ordinary Shares | 10,000 | $0.75 | $7,470 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner | Non-Voting Ordinary Shares | 3,215,434 | N/A | N/A | ||
Sale | FMR LLC 10 percent owner, other: See Re.. | Ordinary shares | 1,022,755 | N/A | N/A | ||
Option | THOMAS FRANK E officer: See Rema.. | Stock Option (Right to Buy) | 10,000 | N/A | N/A | ||
Option | THOMAS FRANK E officer: See Rema.. | Ordinary Shares | 10,000 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 10 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
Orchard Therapeutics: MLD Opportunity Could Be Larger Than Initial Estimates
Orchard Therapeutics: Growing A Position In This Undervalued Gene Therapy Play
Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online
Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Vor Biopharma: Targeted Therapies For Transplants
-
When is Orchard Therapeutics's next earnings date?
Unfortunately, Orchard Therapeutics's (ORTX) next earnings date is currently unknown.
-
Does Orchard Therapeutics pay dividends?
No, Orchard Therapeutics does not pay dividends.
-
How much money does Orchard Therapeutics make?
Orchard Therapeutics has a market capitalization of 380.10M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1346.38% to 6.99M US dollars.
-
What is Orchard Therapeutics's stock symbol?
Orchard Therapeutics plc is traded on the NASDAQ under the ticker symbol "ORTX".
-
What is Orchard Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Orchard Therapeutics?
Shares of Orchard Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Orchard Therapeutics's key executives?
Orchard Therapeutics's management team includes the following people:
- Dr. Bobby Gaspar Ph.D., M.D. Chief Executive Officer, Member of Scientific Advisory Board & Executive Director(age: 60, pay: $712,410)
- Mr. Frank E. Thomas Pres & Chief Operating Officer(age: 55, pay: $586,180)
-
How many employees does Orchard Therapeutics have?
As Jul 2024, Orchard Therapeutics employs 166 workers.
-
When Orchard Therapeutics went public?
Orchard Therapeutics plc is publicly traded company for more then 6 years since IPO on 31 Oct 2018.
-
What is Orchard Therapeutics's official website?
The official website for Orchard Therapeutics is orchard-tx.com.
-
How can i contact Orchard Therapeutics?
Orchard Therapeutics can be reached via phone at +44 20 3808 8286.
Orchard Therapeutics company profile:
Orchard Therapeutics plc
orchard-tx.comExchange:
NASDAQ
Full time employees:
166
Industry:
Biotechnology
Sector:
Healthcare
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
108 Cannon Street
London, EC4N 6EU
London, EC4N 6EU
CIK: 0001748907
ISIN: US68570P2002
CUSIP: 68570P101
